BridgeMD
Compares treatment options for Breast Cancer
Official title Neoadjuvant Chemoradiotherapy Compared to Neoadjuvant Chemotherapy for Luminal-Type Locally Advanced Breast Cancer: A Clinical Study
ClinicalTrials.gov ID: NCT06697938
What this study is testing
- What it's testing
- This study focuses on preoperative treatment modalities for luminal-type locally advanced breast cancer. Based on modern precision radiotherapy technologies such as MRI-Linac, CyberKnife, and VMAT, it aims to compare the pCR rate, breast conserving surgery (BCS) rate, progression-free survival (PFS), and treatment-related side effects between preoperative neoadjuvant chemotherapy and preoperative neoadjuvant SBRT combined with chemotherapy in patients with this type of breast cancer.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Pathologically confirmed invasive breast cancer ;
- Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging);
- Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy...
- Karnofsky performance score ≥80 or ECOG performance status of 0-1;
- No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel;
You likely can't join if
- History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix;
- Inability to complete MRI;
- Inflammatory breast cancer;
- Bilateral or multifocal primary tumors;
- Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to...
See the full eligibility criteria
- Pathologically confirmed invasive breast cancer ;
- Breast MRI showing stages IIB to IIIC (2017 AJCC 8th edition staging);
- Clinical staging confirmed by chest MRI and/or axillary ultrasound, as well as CT scans of the neck, abdomen, and pelvis, and bone scintigraphy, including T and N staging and assessment of distant metastasis;
- Karnofsky performance score ≥80 or ECOG performance status of 0-1;
- No history of allergies to doxorubicin, cyclophosphamide, paclitaxel/docetaxel;
- No prior exposure to radiotherapy, chemotherapy, endocrine therapy, targeted therapy, or immunotherapy.
- History of malignancy at other sites, excluding curable non-melanoma skin cancer and carcinoma in situ of the cervix;
- Inability to complete MRI;
- Inflammatory breast cancer;
- Bilateral or multifocal primary tumors;
- Active infection currently present; clinically evident heart disease; myocardial infarction or cerebrovascular accident within 6 months prior to enrollment.
The study team makes the final eligibility decision.
Where it's taking place
- Chengdu, Sichuan, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chengdu, Sichuan, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.